Organometallic gold(I) and gold(III) complexes for lung cancer treatment

Juzheng Zhang, Yanping Li, Ronghao Fang, Wei Wei, Yong Wang, Jiamin Jin, Feng Yang, Jian ChenFrontiers in Pharmacology 2022 · DOI

Abstract

Metal compounds, especially gold complexes, have recently gained increasing attention as possible lung cancer therapeutics. Some gold complexes display not only excellent activity in cisplatin-sensitive lung cancer but also in cisplatin-resistant lung cancer, revealing promising prospects in the development of novel treatments for lung cancer. This review summarizes examples of anticancer gold(I) and gold (III) complexes for lung cancer treatment, including mechanisms of action and approaches adopted to improve their efficiency. Several excellent examples of gold complexes against lung cancer are highlighted.

Graphical abstract illustrating the application of gold(I/III) agents in lung cancer treatment.

Introduction

Lung cancer remains the leading cause of cancer-related mortality globally. While platinum-based drugs, such as cisplatin, have served as the clinical standard for decades, their utility is significantly hampered by high systemic toxicity and the eventual development of drug resistance by tumor cells.

Researchers are increasingly turning to gold complexes as a viable alternative. Gold possesses a unique "soft" chemical nature, granting it a high affinity for sulfur- and selenium-containing proteins. This allows gold compounds to target biochemical pathways distinct from those affected by platinum, potentially bypassing existing resistance mechanisms. This paper synthesizes recent progress in ligand design and delivery systems intended to address challenges regarding the physiological stability and selectivity of these complexes.

Methodology and Benchmarks

As a comprehensive review, this study systematically categorizes recent literature on gold complexes based on several critical factors:

  • Oxidation States: The review compares the linear coordination of Gold(I) with the square-planar geometry of Gold(III).
  • Ligand Chemistry: The authors evaluate how various scaffolds—including N-heterocyclic carbenes (NHCs), phosphines, sulfur-based ligands, and cyclometalated C^N or C^N^C ligands—influence the stability and biological activity of the metal center.
  • Biological Evaluation: Analysis includes in vitro studies (primarily using the A549 lung cancer cell line) and in vivo models, such as mouse xenografts and transgenic zebrafish embryos used for angiogenesis assays.
  • Advanced Delivery Systems: The review highlights the use of mesoporous silica nanoparticles (MSNs) and biocompatible hydrogels to improve drug bioavailability and reduce off-target effects.

Key Insights: The TrxR "Achilles Heel"

The most significant insight identified is the role of Thioredoxin Reductase (TrxR). Gold complexes act as potent inhibitors of this enzyme, leading to a massive buildup of Reactive Oxygen Species (ROS). This induced oxidative stress triggers mitochondrial dysfunction and eventually leads to programmed cell death (apoptosis).

Furthermore, the shift toward organometallic complexes—featuring direct Gold-Carbon bonds—is crucial. These bonds are more stable under physiological conditions than traditional coordination bonds, preventing the gold from being sequestered by blood proteins before reaching the tumor site. Beyond TrxR, gold complexes exhibit multi-target potential, including DNA G-quadruplex stabilization, proteasome inhibition, and the targeting of aquaporin-3 (AQP3) to block cell migration.

Key Results and Potency

  • Sub-micromolar Potency: Several reviewed complexes showed exceptional cytotoxicity. For instance, Complex 10 achieved an IC50 of 0.03 μM against A549 cells, significantly outperforming many clinical drugs.
  • Superiority to Cisplatin: In mouse models, Complex 19 reduced tumor weight by approximately 62.3%, compared to cisplatin's 44.5%, while demonstrating fewer systemic side effects.
  • Anti-Angiogenesis: Complex 14 was noted for its ability to significantly inhibit blood vessel formation in zebrafish models, suggesting a mechanism to starve tumors of nutrients.
  • Smart Delivery: Encapsulating gold(III) porphyrin in a hydrogel improved its in vivo efficacy and reduced toxicity, providing a clear path toward safer clinical applications.

Limitations and Future Outlook

Despite the promising results, several hurdles remain for the clinical transition of gold-based therapies:

  1. Selectivity: Some potent compounds still show high toxicity toward healthy cells (e.g., MRC-5 fibroblasts). Future research must prioritize ligands that recognize cancer-specific markers.
  2. Pharmacokinetics: There is a need for more rigorous data on how these complexes are metabolized and excreted in complex biological systems.
  3. Mechanism Clarity: While TrxR inhibition is a primary pathway, the full "interactome" of gold complexes in a cellular environment is not yet fully mapped.

In conclusion, organometallic gold complexes represent a potent and versatile class of next-generation therapeutics that could redefine the treatment landscape for lung cancer.

Summary updated

Abstract

Metal compounds, especially gold complexes, have recently gained increasing attention as possible lung cancer therapeutics. Some gold complexes display not only excellent activity in cisplatin-sensitive lung cancer but also in cisplatin-resistant lung cancer, revealing promising prospects in the development of novel treatments for lung cancer. This review summarizes examples of anticancer gold(I) and gold (III) complexes for lung cancer treatment, including mechanisms of action and approaches adopted to improve their efficiency. Several excellent examples of gold complexes against lung cancer are highlighted.
BibTeX
@inproceedings{zhang2022organometallic,
  author = {Juzheng Zhang and Yanping Li and Ronghao Fang and Wei Wei and Yong Wang and Jiamin Jin and Feng Yang and Jian Chen},
  title = {{Organometallic gold(I) and gold(III) complexes for lung cancer treatment}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.979951},
}
Figure